Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics Inc
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
March 22, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
March 21, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 21, 2023
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.
Via
Benzinga
Analyst Expectations for Karuna Therapeutics's Future
March 21, 2023
Via
Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
March 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
ENPH Stock Price Prediction: Can Enphase Energy Really Hit $225?
March 20, 2023
Enphase Energy (ENPH) stock is continuing to rise higher on Monday after an upgrade on Friday gave the company's shares a boost.
Via
InvestorPlace
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’
March 20, 2023
UBS (UBS) stock is a hot topic among traders on Monday with one analyst offering a new rating for the financial company's shares.
Via
InvestorPlace
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data
March 20, 2023
Via
Benzinga
Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
March 20, 2023
Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT.
Via
InvestorPlace
Karuna Surges To Three-Month High On Another Win In Schizophrenia
March 20, 2023
The company is soon planning to ask for FDA approval of KarXT.
Via
Investor's Business Daily
The Latest Analyst Ratings for Karuna Therapeutics
March 02, 2023
Via
Benzinga
Looking Into Karuna Therapeutics's Return On Capital Employed
February 28, 2023
Via
Benzinga
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
March 08, 2023
Via
Benzinga
Analyst Expectations for Karuna Therapeutics's Future
January 27, 2023
Via
Benzinga
5 Analysts Have This to Say About Karuna Therapeutics
December 09, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About Karuna Therapeutics
December 09, 2022
Via
Benzinga
Ciena, Apple And 3 Stocks To Watch Heading Into Monday
March 06, 2023
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Target To Rally 20%? Here Are 10 Other Analyst Forecasts For Thursday
March 02, 2023
Bernstein raised the price target for Okta, Inc. (NASDAQ: OKTA) from $80 to $92. Bernstein analyst Peter Weed maintained a Market Perform rating. Okta shares jumped 16.2% to $83.00 in pre-market...
Via
Benzinga
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
February 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 09, 2023
From
Karuna
Via
Business Wire
Where Karuna Therapeutics Stands With Analysts
December 09, 2022
Via
Benzinga
Expert Ratings for Karuna Therapeutics
December 09, 2022
Via
Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via
Benzinga
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
February 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
January 31, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.